Skip to Content
Merck
CN
  • Metabolism of short-chain fatty acid propionate induces surface expression of NKG2D ligands on cancer cells.

Metabolism of short-chain fatty acid propionate induces surface expression of NKG2D ligands on cancer cells.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2020-10-01)
Rikke Illum Høgh, Sofie Hedlund Møller, Stine Dam Jepsen, Maiken Mellergaard, Astrid Lund, Mikala Pejtersen, Emil Fitzner, Lars Andresen, Søren Skov
ABSTRACT

SCFAs are primarily produced in the colon by bacterial fermentation of nondigestible carbohydrates. Besides providing energy, SCFAs can suppress development of colon cancer. The mechanism, however, remains elusive. Here, we demonstrate that the SCFA propionate upregulates surface expression of the immune stimulatory NKG2D ligands, MICA/B by imposing metabolic changes in dividing cells. Propionate-mediated MICA/B expression did not rely on GPR41/GPR43 receptors but depended on functional mitochondria. By siRNA-directed knockdown, we could further link phosphoenolpyruvate carboxykinase (PEPCK), the rate-limiting enzyme in gluconeogenesis to propionate regulation of MICA/B expression. Moreover, knockdown of Rictor and specific mTOR inhibitors implicated mTORC2 activity with metabolic changes that control MICA/B expression. SCFAs are precursors to short-chain acyl-CoAs that are used for histone acylation thereby linking the metabolic state to chromatin structure and gene expression. Propionate increased the overall acetylation and propionylation and inhibition of lysine acetyltransferases (KATs) that are responsible for adding acyl-CoAs to histones reduced propionate-mediated MICA/B expression, suggesting that propionate-induced acylation increases MICA/B expression. Notably, propionate upregulated MICA/B surface expression on colon cancer cells in an acylation-dependent manner; however, the impact of mitochondrial metabolism on MICA/B expression was different in colon cancer cells compared with Jurkat cells, suggesting that continuous exposure to propionate in the colon may provide an enhanced capacity to metabolize propionate. Together, our findings support that propionate causes metabolic changes resulting in NKG2D ligand surface expression, which holds potential as an immune activating anticancer therapy.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Dimethyl 2-oxoglutarate, 96%
SAFC
RPMI-1640 Medium, HEPES Modification, With 25 mM HEPES, without L-glutamine., liquid, sterile-filtered, suitable for cell culture
Sigma-Aldrich
Sodium propionate, ≥99.0%, BioReagent, suitable for insect cell culture
Sigma-Aldrich
Histopaque®-1077, sterile-filtered, density: 1.077 g/mL
Sigma-Aldrich
Glyceryl tributyrate, ≥99%
Sigma-Aldrich
Penicillin-Streptomycin, Solution stabilized, with 10,000 units penicillin and 10 mg streptomycin/mL, 0.1 μm filtered, BioReagent, suitable for cell culture
Sodium salicylate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Anacardic acid
Supelco
Paraquat dichloride hydrate, PESTANAL®, analytical standard
Sigma-Aldrich
L-Glutamine solution, 200 mM, solution, sterile-filtered, BioXtra, suitable for cell culture
Sigma-Aldrich
Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone, ≥98% (TLC), powder
Sigma-Aldrich
6-Aminonicotinamide, 99%
Sigma-Aldrich
mTOR Inhibitor III, PP242, The mTOR Inhibitor III, PP242 controls the biological activity of mTOR. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
Sigma-Aldrich
BX-795 hydrochloride, ≥98% (HPLC)
Sigma-Aldrich
Sodium butyrate, ≥98.5% (GC)
Sigma-Aldrich
Tetramethylrhodamine methyl ester perchlorate, ≥95%
Sigma-Aldrich
Propidium iodide solution
Sigma-Aldrich
(+)-Etomoxir sodium salt hydrate, ≥98% (HPLC), powder